Tagged with P

Regulation Chester “Chip” Davis, Jr, the President and CEO of the Association for Accessible Medicines (AAM) in the United States, discusses the contradictory nature of Trump’s efforts to lower drug prices.    The President has forcefully pledged to provide relief to these patients and their families, but his own trade policy threatens…

Innovation Patient groups oftentimes serve as the authority on a specific disease when it comes to advancing research.   “Without patient perspective, there is no good medical product development,” Rachel Sherman, the FDA’s principal deputy commissioner proclaimed during her keynote at last week’s NORD’s Rare Disease & Orphan Products Breakthrough Summit.…

Spain Oriol Segarra, CEO of Uriach, describes the Spanish OTC company’s recent developments and transformation from a domestic organization to a truly European player.   These are very interesting times for Uriach; the company is celebrating its 180th anniversary, has just won OTC company of the year, and has invested in…

Malaysia Ch’ng Kien Peng, executive director of Xepa-Soul Pattinson, offers insights on the dynamic healthcare industry in Malaysia and the new government’s key role in supporting the local industry. He also details Xepa-Soul Pattinson’s strong footprint in the country as well as the company’s geographic expansion plans outside of Malaysia.  …

Mexico David Peña Castillo is the President and founder of The Mexican Federation of Rare Diseases (FEMEXER). Here he discusses what makes a patients association. When we find a way to communicate the complexities of rare diseases simply, we can avoid isolating anyone and the potential to uncover important information is…

Biotech Pfizer has teamed up with Bain Capital to launch Cerevel Therapeutics, a biopharmaceutical company based in Boston that will focus on developing treatments for a number of central nervous system (CNS) disorders. It has almost been a year since Pfizer announced that they were to cease R&D in new neuroscience…

Japan Pharma Giant Johnson & Johnson (J&J) are set to swallow Ci:z, the Japanese skincare and cosmetics firm.    In a move to really establish themselves within the Asian skin care market, J&J will shell out 230 billion Japanese yen ($2.05 billion) in cash to take over the share of Ci:z…

Kazakhstan Following the initiative of the Ministry of Health, Kazakhstan engaged in activities to reform its healthcare legislation. The concept of the updated Kazakhstan Code “On People’s Health and Healthcare System” is expected to be proposed for consideration by the countries Government in December 2018 and by their Parliament in the…

Malaysia Indranil Sen, managing director of Ranbaxy Malaysia, a Sun Pharma company, discusses the role of generics in the Malaysian pharmaceutical sector, and their strategy to lead the market, rather than becoming a “me too” generics company.   What have been your main goals that you have set out to achieve…

Spain Francesc Posas, the newly appointed director of the Institute for Research in Biomedicine (IRB Barcelona), explains the evolving role of the institute as a bridge between basic research and concrete patient treatments.  I would like the world to know that there is a lot of outstanding science being done in…

Malaysia Javed Ghulam, CEO of AJ Research & Pharma, offers insights into the dynamic pharma industry in Malaysia and what it takes to be a competitive player in the region.   Being part of AJ Pharmaceuticals Holdings, what is the scope of operations specific to AJ Research & Pharma? AJ Research…

USA After her son was diagnosed with SYNGAP1 – an extremely rare gene mutation – Monica founded Bridge the Gap – SYNGAP Education and Research Foundation to support families of those suffering from the illness and to accelerate the path to better therapies. Here she discusses the importance of community for tackling rare…